Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propofol induction dosing by ideal body weight versus fat-free mass in morbid obesity
IRCT20201024049135N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of propofol in class III obesity (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Blood pressure, Heart rate and 1 more. Started Feb 2021; status: completed.
02
Drugs
propofol
03
Conditions
class III obesity
Beyond the preview
Go deeper on IRCT20201024049135N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201024049135N1.